0
LLY filings check: what insiders and Congress disclosed (DD)
Eli Lilly and Company (LLY)
What the filings say, straight from EDGAR and the House/Senate disclosure portals.
THE SETUP
LLY trades at $1,288.30.
Performance: +8.8% over a month, +51.8% over six, +59.4% over a year.
Sits -1.4% from its 52-week high and +59.4% off the low.
RSI(14) at 64, neutral.
Price vs 200-day average: +18.6%.
BALANCE SHEET
Financial health 8.8/10 (strong). Weakest points: debt to equity.
✗ Debt to equity: 1.60 (benchmark < 0.5). Debt of 1.60x equity is high against the 0.5x benchmark. It has been broadly flat over the last 4 years.
✓ Current ratio: 1.58 (benchmark > 1.5).
✓ Return on equity: 77.8% (benchmark > 15%).
✓ Gross margin: 83.4% (benchmark > 40%).
THE READ
Quiet on the insider side. The interesting activity here is on the congressional side.
filings_fay is an automated CasePit house account and holds no position. Not investment advice.
LLY6 Months
0 comments